文献速递炎症性肠病

儿童急性重症溃疡性结肠炎英夫利西单抗药代动力学与治疗反应的多中心队列研究

Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-08-27

多中心前瞻性队列纳入38例住院儿童急性重症溃疡性结肠炎或未定型炎症性肠病患儿,起始英夫利西单抗中位剂量9.9 mg/kg,建立药代动力学模型并分析其与第7天临床应答、第8周临床缓解、第26周无激素临床缓解及无结肠切除生存的关联。第26周未缓解者英夫利西单抗清除率快于缓解者(P=0.013),但累积药物暴露在临床应答组间无差异。第3天清除率>0.02 L/h与结肠切除相关(HR 58.2,95%CI 6.0-568.6,P<0.001);结论认为基线清除率快与结肠切除及第26周缺乏无激素临床缓解相关,药物暴露不能预测临床结局。

要点

  • 38例患儿起始英夫利西单抗中位剂量9.9 mg/kg,第7天临床应答率71%、第8周临床缓解率55%、第26周无激素临床缓解率43%。
  • 第26周未缓解者英夫利西单抗清除率快于缓解者(P=0.013),但累积药物暴露在临床应答组间无差异。
  • 第3天英夫利西单抗清除率>0.02 L/h与结肠切除相关(HR 58.2,95%CI 6.0-568.6,P<0.001)。

核心结论

  • 在儿童急性重症溃疡性结肠炎中,中位高于说明书剂量的英夫利西单抗治疗下,基线清除率快与结肠切除及第26周缺乏无激素临床缓解相关。
  • 英夫利西单抗药物暴露不能预测临床结局。
  • 更高剂量的英夫利西单抗可能足以优化儿童急性重症溃疡性结肠炎的早期结局。
  • 需要更大规模研究来确定持续强化治疗能否克服快速清除并改善后期结局。

研究设计与样本

  • 多中心前瞻性队列研究,纳入因急性重症溃疡性结肠炎或未定型炎症性肠病开始英夫利西单抗治疗的住院儿童。
  • 共38例参与者接受英夫利西单抗,中位起始剂量9.9 mg/kg。
  • 采集26周内系列英夫利西单抗血清浓度,用于建立药代动力学模型。
  • 分析药代动力学参数估计值与第7天临床应答、第8周临床缓解、第26周无激素临床缓解(采用儿童溃疡性结肠炎活动指数)及无结肠切除生存的关联。

主要发现

  • 第7天临床应答、第8周临床缓解、第26周无激素临床缓解分别发生于71%、55%、43%的参与者。
  • 白蛋白、C反应蛋白、白细胞计数、血小板、体重和抗英夫利西单抗抗体被纳入药代动力学模型作为显著协变量。
  • 第26周未缓解者英夫利西单抗清除率快于缓解者(P=0.013)。
  • 累积英夫利西单抗暴露在临床应答组间无差异。
  • 截至第26周和2年,分别有1例(2.7%)和4例(10.8%)参与者接受结肠切除。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要更大规模研究来确定持续强化治疗能否克服快速清除并改善后期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We aimed to model infliximab (IFX) pharmacokinetics (PK) in pediatric acute severe ulcerative colitis (ASUC) and assess the association between PK parameters, including drug exposure, and clinical response. METHODS: We studied a multicenter prospective cohort of hospitalized children initiating IFX for ASUC or IBD-unclassified. Serial IFX serum concentrations over 26 weeks were used to develop a PK model. We tested the association of PK parameter estimates with day 7 clinical response, week 8 clinical remission, week 26 corticosteroid-free clinical remission (CSF-CR) (using the Pediatric Ulcerative Colitis Activity Index), and colectomy-free survival. RESULTS: Thirty-eight participants received IFX (median initial dose, 9.9 mg/kg). Day 7 clinical response, week 8 clinical remission, and week 26 CSF-CR occurred in 71%, 55%, and 43%, respectively. Albumin, C-reactive protein, white blood cell count, platelets, weight, and antibodies to IFX were significant covariates incorporated into a PK model. Week 26 non-remitters exhibited faster IFX clearance than remitters (P = .013). However, cumulative IFX exposure did not differ between clinical response groups. One (2.7%) and 4 (10.8%) participants underwent colectomy by week 26 and 2 years, respectively. Day 3 IFX clearance >0.02 L/h was associated with colectomy (hazard ratio, 58.2; 95% confidence interval, 6.0-568.6; P < .001). CONCLUSIONS: At median higher-than-label IFX dosing for pediatric ASUC, baseline faster IFX CL was associated with colectomy and at week 26 with lack of CSF-CR. IFX exposure was not predictive of clinical outcomes. Higher IFX dosing may sufficiently optimize early outcomes in pediatric ASUC. Larger studies are warranted to determine whether sustained intensification can overcome rapid clearance and improve later outcomes. CLINICALTRIALS: gov identifier: NCT02799615.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Whaley KG, Xiong Y, Karns R, et al. Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022. PMID: 36031093. doi:10.1016/j.cgh.2022.08.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。